Statistics

Total Visits

Views
Long-Term (104 Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials72

Select a period of time:

Number of views in the range

Views
Long-Term (104 Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials52

Views

Views
March 202515
April 202513
May 20250
June 20250
July 202519
August 20251
September 20254
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore15
Hong Kong10
United States8
Brazil7
United Kingdom3
Austria1
Costa Rica1
Ecuador1
Spain1
Ethiopia1
 

Top cities views

Views
Hong Kong10
São Paulo2
Dallas2
Adana1
Addis Ababa1
Ashburn1
Asunción1
Brasília1
Council Bluffs1
Dourados1